| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 5073 | 2014 |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2550 | 2016 |
| Hematological findings and complications of COVID‐19 E Terpos, I Ntanasis‐Stathopoulos, I Elalamy, E Kastritis, TN Sergentanis, ... American journal of hematology 95 (7), 834-847, 2020 | 2141 | 2020 |
| Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ... J Clin Oncol 23 (34), 8580-7, 2005 | 1611 | 2005 |
| Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders AV Jones, S Kreil, K Zoi, K Waghorn, C Curtis, L Zhang, J Score, R Seear, ... Blood 106 (6), 2162-2168, 2005 | 1170 | 2005 |
| Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P Moreau, J San Miguel, P Sonneveld, MV Mateos, E Zamagni, ... Annals of oncology 28, iv52-iv61, 2017 | 848 | 2017 |
| Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report A Palumbo, S Bringhen, MV Mateos, A Larocca, T Facon, SK Kumar, ... Blood, The Journal of the American Society of Hematology 125 (13), 2068-2074, 2015 | 781 | 2015 |
| Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up MA Dimopoulos, P Moreau, E Terpos, MV Mateos, S Zweegman, G Cook, ... Hemasphere 5 (2), e528, 2021 | 628 | 2021 |
| Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid MA Dimopoulos, E Kastritis, C Bamia, I Melakopoulos, D Gika, M Roussou, ... Annals of Oncology 20 (1), 117-120, 2009 | 579 | 2009 |
| Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group MA Dimopoulos, E Terpos, A Chanan-Khan, N Leung, H Ludwig, ... Journal of clinical oncology 28 (33), 4976-4984, 2010 | 536 | 2010 |
| Organ-specific manifestations of COVID-19 infection M Gavriatopoulou, E Korompoki, D Fotiou, I Ntanasis-Stathopoulos, ... Clinical and experimental medicine 20, 493-506, 2020 | 532 | 2020 |
| Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index E Terpos, R Szydlo, JF Apperley, E Hatjiharissi, M Politou, J Meletis, ... Blood 102 (3), 1064-1069, 2003 | 507 | 2003 |
| Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, ... The lancet oncology 18 (4), e206-e217, 2017 | 491 | 2017 |
| The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS) E Voskaridou, D Christoulas, A Bilalis, E Plata, K Varvagiannis, ... Blood, The Journal of the American Society of Hematology 115 (12), 2354-2363, 2010 | 490 | 2010 |
| Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos, J Bladé, MV Mateos, ... Blood, The Journal of the American Society of Hematology 118 (17), 4519-4529, 2011 | 465 | 2011 |
| Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid MA Dimopoulos, E Kastritis, A Anagnostopoulos, I Melakopoulos, D Gika, ... haematologica 91 (7), 968-971, 2006 | 465 | 2006 |
| International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease E Terpos, G Morgan, MA Dimopoulos, MT Drake, S Lentzsch, N Raje, ... Journal of clinical oncology 31 (18), 2347, 2013 | 445 | 2013 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 443 | 2016 |
| Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement MA Dimopoulos, J Hillengass, S Usmani, E Zamagni, S Lentzsch, ... Journal of Clinical Oncology 33 (6), 657-664, 2015 | 421 | 2015 |
| Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients K Zervas, E Verrou, Z Teleioudis, K Vahtsevanos, A Banti, D Mihou, ... British journal of haematology 134 (6), 620-623, 2006 | 414 | 2006 |
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of Medicine在 med.uoa.gr 的电子邮件经过验证
